Baseline and treatment characteristics
| Characteristic . | All patients (N = 347) . |
|---|---|
| Age at infusion, y | |
| Median | 64.2 |
| Mean | 61.99 |
| Race, n (%) | |
| White | 289 (83.3) |
| Black | 26 (7.5) |
| Other | 32 (9.2) |
| Disease type, n (%) | |
| NHL | 250 (72.0) |
| MM | 80 (23.1) |
| ALL | 17 (4.9) |
| CART products, n (%) | |
| Axi-cel | 133 (46.7) |
| Ide-cel | 42 (14.7) |
| Tisa-cel | 39 (13.7) |
| Cilta-cel | 27 (9.5) |
| Brexu-cel | 26 (9.1) |
| Liso-cel | 18 (6.3) |
| CNS disease at infusion, n (%) | |
| Parenchymal | 14 (4.0) |
| Leptomeningeal | 3 (0.9) |
| CRS | |
| Incidence, all grade, n (%) | 254 (73.2) |
| Grade ≥3, incidence, n (%) | 10 (2.9) |
| ICANS | |
| Incidence, all grade, n (%) | 142 (40.9) |
| Grade ≥3, incidence, n (%) | 61 (27.6) |
| Grade 5, incidence, n (%) | 6 (1.7) |
| Steroid use | |
| Used at least 1 dose, n (%) | 156 (45.0) |
| Hospital admission | |
| >7 d, n (%) | 208 (59.9) |
| ICU transfer, n (%) | 81 (23.3) |
| Characteristic . | All patients (N = 347) . |
|---|---|
| Age at infusion, y | |
| Median | 64.2 |
| Mean | 61.99 |
| Race, n (%) | |
| White | 289 (83.3) |
| Black | 26 (7.5) |
| Other | 32 (9.2) |
| Disease type, n (%) | |
| NHL | 250 (72.0) |
| MM | 80 (23.1) |
| ALL | 17 (4.9) |
| CART products, n (%) | |
| Axi-cel | 133 (46.7) |
| Ide-cel | 42 (14.7) |
| Tisa-cel | 39 (13.7) |
| Cilta-cel | 27 (9.5) |
| Brexu-cel | 26 (9.1) |
| Liso-cel | 18 (6.3) |
| CNS disease at infusion, n (%) | |
| Parenchymal | 14 (4.0) |
| Leptomeningeal | 3 (0.9) |
| CRS | |
| Incidence, all grade, n (%) | 254 (73.2) |
| Grade ≥3, incidence, n (%) | 10 (2.9) |
| ICANS | |
| Incidence, all grade, n (%) | 142 (40.9) |
| Grade ≥3, incidence, n (%) | 61 (27.6) |
| Grade 5, incidence, n (%) | 6 (1.7) |
| Steroid use | |
| Used at least 1 dose, n (%) | 156 (45.0) |
| Hospital admission | |
| >7 d, n (%) | 208 (59.9) |
| ICU transfer, n (%) | 81 (23.3) |
ALL, acute lymphoblastic leukemia; Axi-cel, axicabtagene ciloleucel; Brexu-cel, brexucabtagene; Cilta-cel, ciltacabtagene autoleucel; CNS, central nervous system; CRS, cytokine release syndrome; ICANS, immune effector cell–associated neurotoxicity syndrome; Ide-cel, idecabtagene vicleucel; Liso-cel, lisocabtagene maraleucel; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; Tisa-cel: tisagenlecleucel.